Anna Gramling, MD
Rheumatology · Plainfield, INNPI 1508033408
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 821 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by Amgen at 27.2% of the total. Reporting peaked in 2024 at $2,434 and has fallen 52.2% since, to $1,162 in 2025.
Across 821 payments — averaging $14.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- AbbVie$2K
- Pfizer$1K
- Johnson & Johnson$1K
- Novartis$994
- E.r. Squibb & Sons, L.L.C.$600
- plus $2K from 18 others
What the payments were for
- Food & beverage$11,87998%
- Education$2252%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 236 | $3,293 |
| AbbVie | 186 | $2,295 |
| Pfizer | 127 | $1,441 |
| Johnson & Johnson | 38 | $1,014 |
| Novartis | 77 | $994 |
| E.r. Squibb & Sons, L.L.C. | 28 | $600 |
| AstraZeneca(2 entities) | 26 | $504 |
| UCB, Inc. | 29 | $499 |
| Lilly USA, LLC | 23 | $426 |
| Genentech USA, Inc. | 11 | $194 |
| Sanofi | 7 | $174 |
| GSK | 10 | $169 |
| ANI Pharmaceuticals, Inc. | 6 | $159 |
| Sobi, Inc | 3 | $65 |
| Regeneron Healthcare Solutions, Inc. | 3 | $64 |
| Bristol Myers Squibb | 2 | $45 |
| Mallinckrodt Hospital Products Inc. | 2 | $38 |
| Argenx US, Inc. | 1 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Radius Health, Inc. | 1 | $19 |
| Aurinia Pharma U.S., Inc. | 1 | $19 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
| Biocon Biologics Inc | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SIMPONI ARIA$232
- Tremfya$232
How this compares
$12,104 in reported general payments places this provider in the 85th percentile of 106 rheumatology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 82 | $669,404 |
| Enbrel SureclickEtanercept | 76 | $624,038 |
| IlarisCanakinumab/Pf | 11 | $405,918 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 34 | $245,562 |
| Orencia ClickjectAbatacept | 37 | $226,227 |
| Xeljanz XrTofacitinib Citrate | 28 | $204,426 |
| Cosentyx Sensoready PenSecukinumab | 11 | $160,192 |
| RinvoqUpadacitinib | 18 | $113,402 |
| Cimzia (2 Pack)Certolizumab Pegol | 13 | $105,016 |
| BenlystaBelimumab | 20 | $95,063 |
| OtezlaApremilast | 19 | $94,468 |
| EnbrelEtanercept | 13 | $93,226 |
| Humira(Cf)Adalimumab | 12 | $76,126 |
| SaphneloAnifrolumab-Fnia | 13 | $67,068 |
| KevzaraSarilumab | 15 | $64,986 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisIlaris | $994 | $405,91811 claims |
| AbbVieRinvoq, Humira(Cf) | $2,295 | $189,52830 claims |
| AmgenOtezla, Enbrel | $3,293 | $187,69432 claims |
| UCB, Inc.Cimzia (2 Pack) | $499 | $105,01613 claims |
| GSKBenlysta | $169 | $95,06320 claims |
| AstraZenecaSaphnelo | $504 | $67,06813 claims |
| SanofiKevzara | $174 | $64,98615 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $18 | $94012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 106 rheumatology providers in Indiana.
Other rheumatology in Plainfield
- Sahitya MallipeddiPlainfield$9K
- David BattIndianapolis$577K
- Kathleen ThomasNoblesville$511K
- Keith ReichDyer$193K
- Douglas SmithIndianapolis$147K
- Ahmad SalahMerrillville$139K
- Inna AroutiounovaIndianapolis$102K
- James CohenIndianapolis$76K
- Nina RamessarFort Wayne$75K
- Anita ZachariahMunster$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.